Soligenix is progressing with its Phase 3 CTCL study and vaccine programs, NRx Pharmaceuticals has secured funding for its interventional psychiatry clinic network, Telomir Pharmaceuticals has unveiled a new antimicrobial drug candidate, Creative Biolabs is enhancing antibody functionality, Tevard Biosciences is showing promising results in DMD therapy, Aston Bay Holdings is partnering for project development, NanoViricides is advancing treatments for Measles and MPox, Silo Pharma is conducting safety studies for its PTSD treatment, Annovis Bio is launching a Phase 3 trial for early Alzheimer’s, and Glucotrack is moving forward with a clinical trial for its Continuous Blood Glucose Monitor system. The study on Takotsubo cardiomyopathy highlights the need for further research to improve treatment outcomes.
